Results 21 to 30 of about 16,038 (249)

Convalescent plasma therapy: A passive therapy for an aggressive COVID‐19 [PDF]

Journal of Medical Virology, 2020
As of May 19, 2020, there are in total 4,986,200 laboratory-confirmed Coronavirus disease-2019 (COVID-19) cases. 2% (45,425) out of 2,657,390 active COVID-19 cases are critically ill and might be requiring intensive care support. Unfortunately, even after six months since its first detection, we still do not have any definitive treatment options for ...
Sahu, Kamal Kant, Jindal, Vishal, Siddiqui, Ahmad Daniyal, Cerny, Jan, Gerber, Jonathan M.   +4 more
openaire   +3 more sources

Response to convalescent plasma is not influenced by patient blood type

Global Journal of Transfusion Medicine, 2021
Background: SARS-CoV2 virus is associated with 580,000 deaths and 32.5 million cases of COVID-19 infection in the United States. Data exist suggesting a correlation between blood type and disease acquisition and severity. No such data exist between blood
William R Hartman, Aaron S Hess, Joseph P Connor   +2 more
doaj   +1 more source

Safety and efficacy of convalescent plasma for COVID-19: the preliminary results of a clinical trial [PDF]

Клиническая практика, 2020
Background. The lack of effective etiotropic therapy for COVID-19 has prompted researchers around the globe to seekr various methods of SARS-CoV-2 elimination, including the use of convalescent plasma. Aim. The aim of this work was to study the safety
Vladimir P. Baklaushev, Alexander V. Averyanov, Anna G. Sotnikova, Anastasia S. Perkina, Alexander V. Ivanov, Gaukhar M. Yusubalieva, Oksana N. Novikova, Valentina E. Shikina, Nikolay V. Dupik, Anna G. Kedrova, Andrey E. Sanzharov, Elena V. Shirshova, Olga I. Balionis, Vladimir T. Valuev-Elliston, Natalia F. Zakirova, Yaroslav N. Glazov, Irina A. Panukhina, Nikolay A. Soloviev, Alexei G. Vinokurov, Yu. V. Ivanov, Valentin N. Vasilev, Tatyana V. Klypa, Alexander V. Troitsky   +22 more
doaj   +1 more source

Case Report: Serial Cases: Prolongation of High Immunoglobulin G Level in Repetitive COVID-19 Convalescence Plasma Donor in Saiful Anwar Hospital Malang, Indonesia

Frontiers in Immunology, 2021
BackgroundConvalescent plasma therapy is expected to be a promising alternative to supportive therapy during the SARS-CoV-2 pandemic outbreak. Altered immune response in repetitive convalescent plasma donors has not been widely studied.
Nina Nurarifah, Herwindo Pudjo Brahmantyo, Shinta Oktya Wardhani, Djoko Heri Hermanto, Putu Moda Arsana   +4 more
doaj   +1 more source

Convalescent plasma and hyperimmune globulin therapy in COVID-19 [PDF]

Expert Review of Clinical Immunology, 2021
Introduction: Severe acute respiratory syndrome causing coronavirus SARS-CoV-2 (coronavirus disease 2019 (COVID-19)) has recently resulted in the recent global pandemic. As convalescent plasma (CP) therapy has been used with success in several viral infections before, it has become a treatment of choice.
openaire   +2 more sources

CONVALESCENT PLASMA THERAPY FOR COVID-19: STATE OF THE ART

Clinical Microbiology Reviews, 2020
Convalescent blood product therapy has been introduced since early 1900s to treat emerging infectious disease based on the evidence that polyclonal neutralizing antibodies can reduce duration of viremia. Recent large outbreaks of viral diseases for whom effective antivirals or vaccines are still lacking has revamped the interest in convalescent plasma ...
Daniele Focosi, Julian W Tang, Arthur O Anderson, Marco Tuccori   +3 more
openaire   +10 more sources

Effectiveness of Convalescent Plasma Therapy in Treating COVID-19: an Evidence-based Case Report

Acta Medica Indonesiana, 2022
Background: Convalescent plasma is a potentially beneficial, tolerable, and available additional treatment option for COVID-19. This study aims to evaluate whether the administration of convalescent plasma therapy leads to improved clinical outcomes in ...
Mira Yulianti, Christian Johan, Gurmeet Singh, Eric Daniel Tenda, Herikurniawan Herikurniawan, I Putu Eka Krisnha Wijaya   +5 more
doaj   +2 more sources

Convalescent Plasma in the Treatment of Severe COVID-19: A Systematic Review and Meta-Analysis

Iranian Journal of Public Health, 2020
Background: COVID-19 is a public health emergency of international concern. Its incidence rates and mortality are very high; however, so far, an effective drug treatment remains unknown.
Xuanguo ZHANG, Li XI, Fang PANG, Yan DU, Qiuzhen YUAN, Minjuan SHI, Jiping LIU, Hui MA, Bo LI   +8 more
doaj   +1 more source

COVID-19 outcome is not affected by anti-CD20 or high-titer convalescent plasma in immunosuppressed patients

Scientific Reports, 2023
The role of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) convalescent plasma in the treatment of Coronavirus Disease 2019 (COVID-19) in immunosuppressed individuals remains controversial. We describe the course of COVID-19 in patients who
Mary J. Kasten, Brian D. Lahr, Anusha Parisapogu, Zachary A. Yetmar, John C. O’Horo, Robert Orenstein, Pablo Moreno Franco, Raymund R. Razonable, Paschalis Vergidis, Aditya S. Shah, Mark J. Enzler, David J. Inwards, Philippe R. Bauer   +12 more
doaj   +1 more source

Convalescent Plasma Reduces Mortality and Decreases Hospitalization Stay in Patients with Moderate COVID-19 Pneumonia

Metabolites, 2021
Humans infected with SARS-CoV-2 may develop COVID-19, which manifests across a wide spectrum of clinical severity ranging from mild upper respiratory tract illnesses to diffuse viral pneumonia, causing acute respiratory failure.
Maamoun Basheer, Elias Saad, Dorin Shlezinger, Nimer Assy   +3 more
doaj   +1 more source